Fatty acid relationships in former cannabis users with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 280-285

  Monterrubio, Sharon ^a   Solowij, Nadia ^a   Meyer, Barbara J ^a   Turner, Nigel ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Anandamide; Cannabis; Clozapine; Fatty acids; Schizophrenia; Stress

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; CARBON; FATTY ACID; LINOLEIC ACID; MONOUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ADULT; ARTICLE; BRIEF SYMPTOM INVENTORY; CANNABIS ADDICTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; RATING SCALE; SAMPLE; SCHIZOPHRENIA; STRESS;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; ARACHIDONIC ACID; CLOZAPINE; DEPRESSION; FATTY ACIDS; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 33344463601     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.08.013     Document Type: Article

References (39)

1. M.M. Antony, P.J. Bieling, B.J. Cox, M.W. Enns, and R.P. Swinson Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample Psychol. Assess. 10 1998 176 181
2. G. Barcelo-Coblijn, K. Kitajka, L.G. Puskas, E. Hogyes, A. Zvara, L. Hackler, and T. Farkas Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid Biochim. Biophys. Acta 1632 2003 72 79
3. A. Berger, G. Crozier, T. Bisogno, P. Cavaliere, S. Innis, and V. Di Marzo Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets Proc. Natl. Acad. Sci. U. S. A. 98 2001 6402 6406
4. T.A. Brown, B.F. Chorpita, W. Korotitsch, and D.H. Barlow Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples Behav. Res. Ther. 35 1997 79 89
5. B. Bühler, M. Hambrecht, W. Loffler, W. an der Heiden, and H. Hafner Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes Schizophr. Res. 54 2002 243 251
6. A. Calignano, G. La Rana, and D. Piomelli Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide Eur. J. Pharmacol. 419 2001 191 198
7. B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. Copolov Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use Neuroscience 103 2001 9 15
8. I.N. De Gomez Dumm, M.J. de Alaniz, and R.R. Brenner Effect of catecholamines and beta-blockers on linoleic acid desaturation activity Lipids 13 1978 649 652
9. N. De Marchi, L. De Petrocellis, P. Orlando, F. Daniele, F. Fezza, and V. Di Marzo Endocannabinoid signalling in the blood of patients with schizophrenia Lipids Health Dis. 2 2003 5
10. L. Derogatis BSI: Administration, Scoring, and Procedures Manual Third ed. 1993 National Computer Systems Minneapolis
11. A. Giuffrida, F.M. Leweke, C.W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkotter, and D. Piomelli Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms Neuropsychopharmacology 29 2004 2108 2114
12. H.S. Hansen, L. Lauritzen, B. Moesgaard, A.M. Strand, and H.H. Hansen Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity Biochem. Pharmacol. 55 1998 719 725
13. D.F. Horrobin The effects of antipsychotic drugs on membrane phospholipids: a possible novel mechanism of action of clozapine M. Peet I. Glen D.F. Horrobin Phospholipid Spectrum Disorders in Psychiatry and Neurology Second ed. 2003 Marius Carnforth, UK 271 276
14. D.F. Horrobin Eicosapentaenoic acid derivatives in the management of schizophrenia M. Peet I. Glen D.F. Horrobin Phospholipid Spectrum Disorders in Psychiatry and Neurology Second ed. 2003 Marius Press Carnforth, UK 371 376
15. D.F. Horrobin Phospholipid and fatty acid biochemistry in schizophrenia M. Peet A.I.M. Glen D.F. Horrobin Phospholipid Spectrum Disorders in Psychiatry and Neurology Second ed. 2003 Marius Press Carnforth, UK 123 162
16. D.J. Kavanagh, G. Waghorn, L. Jenner, D.C. Chant, V. Carr, M. Evans, H. Herrman, A. Jablensky, and J.J. McGrath Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample Schizophr. Res. 66 2004 115 124
17. F.M. Leweke, A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli Elevated endogenous cannabinoids in schizophrenia NeuroReport 10 1999 1665 1669
18. C.M. Loughland, V.J. Carr, and T.J. Lewin The NISAD Schizophrenia Research Register: why do we need a database of schizophrenia volunteers? Aust. N. Z. J. Psychiatry. 35 2001 660 667
19. P.F. Lovibond Long-term stability of depression, anxiety, and stress syndromes J. Abnorm. Psychology 107 1998 520 526
20. P.F. Lovibond, and S.H. Lovibond The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the beck depression and anxiety inventories Behav. Res. Ther. 33 1995 335 343
21. M. Maes, A. Christophe, E. Bosmans, A.H. Lin, and H. Neels In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress Biol. Psychiatry 47 2000 910 920
22. S.P. Mahadik, D. Evans, and H. Lal Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia Biol. Psychiatry 25 2001 463 493
23. I. Myin-Germeys, J. Van Os, J.E. Schwartz, A.A. Stone, and P.A. Delespaul Emotional reactivity to daily life stress in psychosis Arch. Gen. Psychiatry 58 2001 1137 1144
24. T.E. Ollis, B.J. Meyer, and P.R. Howe Australian food sources and intakes of omega-6 and omega-3 polyunsaturated fatty acids Ann. Nutr. Metab. 43 1999 346 355
25. P.V. Piazza, and M. Le Moal The role of stress in drug self-administration Trends Pharmacol. Sci. 19 1998 67 74
26. S. Potvin, E. Stip, and J.Y. Roy Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses Int. Clin. Psychopharmacol. 18 2003 121 132
27. A.J. Richardson, S.J. Allen, J.V. Hajnal, I.J. Cox, T. Easton, and B.K. Puri Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 1513 1521
28. L. Ridges, R. Sunderland, K. Moerman, B. Meyer, L. Astheimer, and P. Howe Cholesterol lowering benefits of soy and linseed enriched foods Asia Pac. J. Clin. Nutr. 10 2001 204 211
29. V. Saraswathi, G. Wu, M. Toborek, and B. Hennig Linoleic acid-induced endothelial activation: role of calcium and peroxynitrite signaling J. Lipid Res. 45 2004 794 804
30. H.H. Schmid, and E.V. Berdyshev Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function Prostaglandins Leukot. Essent. Fat. Acids 66 2002 363 376
31. C. Spencer, D. Castle, and P.T. Michie Motivations that maintain substance use among individuals with psychotic disorders Schizophr. Bull. 28 2002 233 247
32. N. Stella, and D. Piomelli Receptor-dependent formation of endogenous cannabinoids in cortical neurons Eur. J. Pharmacol. 425 2001 189 196
33. L.N.P. Voruganti, P. Slomka, P. Zabel, A. Mattar, and A.G. Awad Cannabis induced dopamine release: an in-vivo SPECT study Psychiatry Res. 107 2001 173 177
34. E.F. Walker, and D. Diforio Schizophrenia: a neural diathesis-stress model Psychol. Rev. 104 1997 667 685
35. W.C. Willett, L. Sampson, M.J. Stampfer, B. Rosner, C. Bain, J. Witschi, C.H. Hennekens, and F.E. Speizer Reproducibility and validity of a semiquantitative food frequency questionnaire Am. J. Epidemiol. 122 1985 51 65
36. Xyris FoodWorks Third ed. 2002 Xyris Software Brisbane, Australia
37. J.K. Yao Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia M. Peet I. Glen D.F. Horrobin Phospholipid Spectrum Disorders in Psychiatry and Neurology Second ed. 2003 Marius Press Carnforth, UK 193 212
38. K. Zavitsanou, T. Garrick, and X.F. Huang Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 2004 355 360
39. B. Zenor, G. Weesner, and P. Malven Endocrine and other responses to acute administration of cannabinoid compounds to non-stressed male calves Life Sci. 65 1999 125 133